Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

Mar 14 2022

• By Alaric DeArment

Cancer-cells-pink-color_1200x675 — Nektar and BMS announced the failure of their Phase III melanoma study • Source: Shutterstock

Related Content

Nektar/Bristol Show Promise With Double IO Combo, But Numbers Are Small

Feb 20 2019

Nektar Pins Falling Cancer Response Rate On Manufacturing Problem

Aug 09 2019

Bristol Goes In Big On New Valentine Nektar

Feb 14 2018

Scrip's Rough Guide To IL-2: Mother Of All Cytokines

Mar 26 2018

Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days

Apr 12 2021

Anaveon To Take A Different Clinical Path With Novel IL-2 Therapy

Jun 24 2021

Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner

Mar 30 2021

Asher Bio Raises $108m For Immune Cell-Specific Therapies

Sep 01 2021

Related Companies

Nektar Therapeutics

Bristol Myers Squibb Company

Merck & Co., Inc.

Roche Holding AG

Johnson & Johnson

Eli Lilly and Company

Novartis AG

Nestle Health Science

Sanofi

Anaveon AG

Asher Biotherapeutics, Inc.

Xilio Therapeutics, Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window